

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PU60401	INTERNATIONAL APPLICATION NO. PCT/US2004/022946 10564947
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Gardner, et al.	
		INT FILING DATE 16 July 2004	GROUP

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	SMYTHE, M.A., et al. Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. American Journal of Hematology, 2002, Vol. 71, pages 50-52, especially p. 52.
	KONDO, L.M., et al. Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia. Annals of Pharmacotherapy, April 2001, Vol. 35, pages 440-451, especially pages 442 and 446.
	ADKINS, J.C. et al. Lepirudin: a review of its potential place in the management of thrombotic disorders. BioDrugs. Sept. 1998, Vol. 10, No.3 pages 227-255, especially p. 228, 232-233, 239-241, 247, and 249-251.
	LAPOSATA, M.L., et al. College of American Pathologists conference XXXI on laboratory monitoring of anticoagulant therapy: The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Archives of Pathology and Laboratory Medicine. September 1998, Vol. 122, No. 9, pages 799-807, especially pages 801 and 804-805.
	HURSTING, M.J. et al. The international normalized ratio during concurrent warfarin and argatroban anticoagulation: differential contributions of each agent and effects of the choice of thromboplastin used. Clinical Chemistry. 1999, Vol. 45, No. 3, pages 409-412, especially p. 411.
	no copies of lined-through references provided with application
EXAMINER /Lora E Barnhart/	DATE CONSIDERED 12/23/2008

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

n:\soma\cases\pu60399\us national transmittal.doc

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /leb/